Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire•03/11/2026•07:00 ET
0
Key Highlights
- ➤$558.9 million cash, restricted cash and marketable securities at September 30, 2026
- ➤Cash runway extends into the second half of 2028 under current operating plan
- ➤ARV-6723 Phase 1/2 dosing initiated in advanced solid-tumor patients
- ➤ARV-102 data showed improved eye movement correlated with LRRK2 biomarker reductions
- ➤Revenue fell to $0.5 million from $41.9 million year over year
Expert Statements
Randy Teel, President and Chief Executive Officer of Arvinas
“We executed strongly during the quarter and are entering an important period of clinical milestones that we believe will demonstrate the promise of our clinical-stage protein degraders.”
Randy Teel, President and Chief Executive Officer of Arvinas
“We are prioritizing investments where emerging evidence supports our goal of creating transformative medicines for patients.”
Randy Teel, President and Chief Executive Officer of Arvinas
“The upcoming data from our BCL6, polyQ-AR, and HPK1 degraders will begin to define the opportunity for these programs to change the treatment landscape, and we are grateful to the patients, investigators, and employees whose commitment makes this progress possible.”
– Initiated dosing in a Phase 1/2 trial of ARV-6723, an immuno-oncology oral PROTAC designed to degrade HPK1, a negative regulator of immune activation –
– Reaffirmed commitment to share clinical data from three Phase 1 programs - ARV-393, ARV-027 and ARV-6723 - in 4Q 2026 and 2027 –
Get started
Create a free account to read the full story.